证券简称：仟源医药 证券代码：300254 上海荣正企业咨询服务（集团）股份有限公司 关于 山西仟源医药集团股份有限公司 首次授予相关事项 之 独立财务顾问报告 目 录 一、 释义 本独立财务顾问报告中，除非文义载明，下列简称具有如下含义： 仟源医药、公司、上市公司 指 山西仟源医药集团股份有限公司 本激励计划、本计划、本次限制 指 山西仟源医药集团股份有限公司 2025 年限制性股票激励计划 性股票激励计划、股权激励计划 上海荣正企业咨询服务（集团）股份有限公司关于山西仟源医 独立财务顾问报告、本报告 指 药集团股份有限公司 2025 年限制性股票激励计划首次授予相 关 事项之独立财务顾问报告 本独立财务顾问 指 上海荣正企业咨询服务（集团）股份有限公司 公司根据本激励计划规定的条件和价格，授予激励对象一定数 限制性股票 指 量的公司股票，该等股票设置一定期限的限售期，在达到本激 励计划规定的解除限售条件后，方可解除限售流通 按照本激励计划规定，获得限制性股票的公司（含分公司及控 激励对象 指 股子公司，下同）员工 授予日 指 公司向激励对象授予限制性股票的日期，授予日必须为交易日 授予价格 指 公司授予激 ...

Core Viewpoint - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. is implementing a 2025 restricted stock incentive plan, which has received necessary approvals and is in compliance with relevant laws and regulations [1][3][6]. Group 1: Legal Framework and Compliance - The law firm Grandall (Shanghai) has been appointed as the legal advisor for the company's 2025 restricted stock incentive plan, ensuring compliance with the Company Law, Securities Law, and other relevant regulations [1][2]. - The law firm has confirmed that the legal opinion provided is based on existing facts and applicable laws, and it will bear legal responsibility for the opinion issued [2][3]. Group 2: Approval Process - The approval process for the incentive plan included multiple meetings: the board meeting on July 21, 2025, where the draft plan was approved, and the shareholders' meeting on August 7, 2025, which also approved the plan [3][4]. - The board of directors held a subsequent meeting on August 8, 2025, to approve the first grant of restricted stocks to the incentive targets [4][6]. Group 3: Grant Details - The first grant of restricted stocks is set for August 8, 2025, with a total of 7.95 million shares to be granted to 171 eligible incentive targets at a price of 5.60 yuan per share [6][7]. - The granting conditions include compliance with specific financial and regulatory criteria, ensuring that the company meets the necessary standards for stock incentives [5][6]. Group 4: Conclusion - The law firm concludes that the incentive plan's first grant has obtained the required authorizations and approvals, and all conditions for granting the restricted stocks have been met [6][7].

Core Points - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. announced the repurchase and cancellation of 60,000 restricted stocks from the 2024 incentive plan due to one incentive object leaving the company [1][4][8] - The repurchase price is set at 4.73 yuan per share, with interest equivalent to the bank's term deposit rate [1][6] - The total amount for the repurchase is 283,800 yuan, sourced from the company's own funds [6][8] Decision Process and Disclosure - The decision to repurchase was approved during the 31st meeting of the fifth board of directors on August 8, 2025, following the necessary procedures and disclosures [1][4] - The supervisory board confirmed that no objections were raised during the public notice period regarding the incentive plan [2][4] Stock Structure Changes - Before the repurchase, the total number of restricted shares was 21,014,468, which will decrease to 20,954,468 after the cancellation [7] - The total share capital will change from 248,318,563 to 248,258,563 shares [7] Impact on the Company - The repurchase and cancellation of the restricted stocks will not significantly affect the company's financial status, operational results, or the ongoing implementation of the incentive plan [4][8] - The management team is committed to fulfilling their responsibilities and creating value for shareholders [4][8] Committee and Legal Opinions - The Compensation and Assessment Committee approved the repurchase, confirming compliance with relevant regulations and the accuracy of the number and price of the stocks [8] - Legal opinions from Guohao Law Firm indicate that the company has obtained necessary approvals and must submit the matter for shareholder approval [8]

上述回购注销事项符合《上市公司股权激励管理办法》、《公司 2024 年限 制性股票激励计划》的相关规定，并已履行了必要的决策程序。本次回购注销的 已获授但尚未解除限售的限制性股票激励对象人员准确、数量无误、价格准确。 薪酬与考核委员会同意公司本次回购注销该部分限制性股票。 特此公告 山西仟源医药集团股份有限公司 薪酬与考核委员会 二〇二五年八月八日 山西仟源医药集团股份有限公司 薪酬与考核委员会关于回购注销 2024 年限制性股票激励 计划部分限制性股票的核查意见 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 8 日 召开第五届董事会第三十一次会议审议通过了《关于回购注销 2024 年限制性股 票激励计划部分限制性股票的议案》，根据《上市公司股权激励管理办法》、《深 圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》的相关规定， 薪酬与考核委员会对公司本次拟回购注销限制性股票的数量及涉及的激励对象 名单进行核查，并发表核查意见如下： 经审核，薪酬与考核委员会认为，公司 2024 年限制性股票激励计划中有 1 名激励对象已离职，不再具备激励对象资格，根据《上市公司股权激励 ...

职务 限制性股票总 予时股本总 票数量（万股） 数的比例 额的比例 核心骨干人员（171 人） 795 86.89% 3.20% 山西仟源医药集团股份有限公司 占本计划授予 占本计划授 合计 795 86.89% 3.20% 董事会 二〇二五年八月九日 获授的限制性股 划提交股东会时公司股本总额的 20%。 山西仟源医药集团股份有限公司 注：1、上述任何一名首次授予的激励对象通过全部在有效期内的股权激励计划获授的本公司股票均 未超过公司总股本的 1%。公司全部在有效期内的激励计划所涉及的标的股票总数累计不超过股权激励 计 ...

Core Viewpoint - The Compensation and Assessment Committee of Shanxi Qianyuan Pharmaceutical Group Co., Ltd. has reviewed and approved the list of initial grant recipients for the 2025 restricted stock incentive plan, confirming that all recipients meet the necessary legal and regulatory conditions [1][2]. Group 1 - The committee's review was based on relevant laws and regulations, including the Company Law, Securities Law, and the Management Measures for Equity Incentives of Listed Companies [1]. - The committee identified that none of the recipients were deemed inappropriate candidates by the stock exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months [1]. - The committee has agreed to grant a total of 7.95 million shares of restricted stock to 171 recipients, with the grant date set for August 8, 2025 [2].

Core Viewpoint - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. has approved the 2025 Restricted Stock Incentive Plan, granting 7.95 million shares of restricted stock at a price of 5.60 yuan per share to 171 eligible incentive objects on August 8, 2025 [1][11]. Summary by Sections Incentive Plan Overview - The total number of restricted stocks to be granted under the incentive plan does not exceed 9.15 million shares, accounting for 3.68% of the company's total share capital [2]. - The first grant involves 7.95 million shares, which is 86.89% of the total grant amount [10]. - The lock-up periods for the granted restricted stocks are set at 12, 24, and 36 months [2]. Performance Assessment Criteria - The performance assessment for the first grant period requires a net profit growth rate of no less than 25.43% in 2025 compared to 2024 [5]. - For the second grant period in 2026, the required growth rate is 71.04%, and for the third grant period in 2027, it is 133.96% [6][7]. Decision-Making Process - The decision-making process for the incentive plan has been completed, with necessary approvals obtained from the board and the compensation and assessment committee [9][11]. - The plan has been publicly disclosed for 10 days without any objections [9]. Legal and Financial Opinions - Legal opinions confirm that the incentive plan complies with relevant laws and regulations, and the conditions for granting the restricted stocks have been met [12][13]. - The independent financial advisor has also affirmed that the plan's implementation does not harm the interests of the company and its shareholders [12][13]. Financial Impact - The implementation of the restricted stock incentive plan is expected to have a limited impact on the company's financial status and operating results [11][12]. - The funds raised from the stock grant will be used to supplement the company's working capital [12].

Group 1 - The core point of the article is that QianYuan Pharmaceutical announced the convening of its 31st meeting of the 5th Board of Directors via communication voting on August 8, 2025, to discuss the proposal for the 4th extraordinary shareholders' meeting of 2025 [2] - For the year 2024, QianYuan Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 96.68%, DNA gene preservation and prenatal environment testing services account for 1.93%, health food accounts for 0.79%, other businesses account for 0.51%, and commercial activities account for 0.1% [2]

山西仟源医药集团股份有限公司 2025 年限制性股票激励计划激励对象首次授予名单（截止授予日） 董事会 二〇二五年八月九日 | 职务 | 获授的限制性股 | 占本计划授予 | 占本计划授 | | --- | --- | --- | --- | | | 票数量（万股） | 限制性股票总 | 予时股本总 | | | | 数的比例 | 额的比例 | | 人） 核心骨干人员（171 | 795 | 86.89% | 3.20% | | 合计 | 795 | 86.89% | 3.20% | 2、以上合计数据与各明细数相加之和在尾数上如有差异是由于四舍五入所造成。 山西仟源医药集团股份有限公司 2025 年限制性股票激励计划激励对象首次授予情况： 注：1、上述任何一名首次授予的激励对象通过全部在有效期内的股权激励计划获授的本公司股票均 未超过公司总股本的 1%。公司全部在有效期内的激励计划所涉及的标的股票总数累计不超过股权激励计 划提交股东会时公司股本总额的 20%。 ...

1、获授权益的激励对象不存在《管理办法》规定的不得成为激励对象的情 形： （1）最近 12 个月内被证券交易所认定为不适当人选； 山西仟源医药集团股份有限公司 薪酬与考核委员会关于公司 2025 年限制性股票激励计划 激励对象首次授予名单（截止授予日）的核查意见 山西仟源医药集团股份有限公司（以下简称"公司"）薪酬与考核委员会根 据《公司法》、《证券法》、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）等有关法律法规、规范性文件以及《公司 2025 年限制性股票激励 计划》（以下简称"《激励计划》"）、《公司章程》的有关规定，对公司 2025 年限制性股票激励计划（以下简称"本激励计划"）激励对象首次授予名单（截 止授予日）进行审核，发表如下意见： （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； 2、获授权益的激励对象符合《激励计划》规定的激励对象条件，其中无董 事、高管。 综上，薪酬与考核委员会认为本激励计划激励对象均符合相关法律法规和规 范性文件所规定的条件，符合《激励计划》规 ...